Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00585169 · ClinicalTrials.gov registry record · Phase 2
Memantine Treatment Study of Pathological Gambling
A Phase 2 study of Pathological Gambling, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 2
- Study locations
NCT00585169 is a Phase 2 study of Pathological Gambling that has completed, run by Yale University. The registered enrollment target is 29 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00585169, a Phase 2 study of Pathological Gambling, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of the proposed study is to evaluate the efficacy and safety of the drug memantine in individuals with pathological gambling (PG). Thirty subjects with DSM-IV PG will receive 10 weeks of open-label treatment with memantine. The hypothesis to be tested is that memantine will be effective and well tolerated in patients with PG. We hypothesize that memantine will reduce the severity of gambling symptoms and improve patients' overall functioning. This study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.
Conditions Studied
Interventions
- DRUG Memantine Hydrochloride
Study Locations (2)
Connecticut
- Yale University School of Medicine - New Haven
Minnesota
- University of Minnesota Medical Center, Fairview - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00585169
The ClinicalTrials.gov registry entry for NCT00585169 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pathological Gambling appearing as the primary indexed condition, and to 1 intervention - of which Memantine Hydrochloride is the first listed.
NCT00585169 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Connecticut, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00585169 about?
NCT00585169 is a clinical study titled "Memantine Treatment Study of Pathological Gambling". The goal of the proposed study is to evaluate the efficacy and safety of the drug memantine in individuals with pathological gambling (PG). Thirty subjects with DSM-IV PG will receive 10 weeks of open-label treatment with memantine. The hypothesis to be tested is that memantine will be effective and...
What is the current status of trial NCT00585169?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2007-12. Estimated completion is 2011-12.
What conditions does trial NCT00585169 study?
This clinical trial studies the following conditions: Pathological Gambling.
What interventions are being tested in trial NCT00585169?
The interventions under investigation include: Memantine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00585169?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00585169 being conducted?
This trial has 2 study locations across Connecticut, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pathological Gambling
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.